Company Update (NASDAQ:ARNA): Arena Pharmaceuticals, Inc. and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally


Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it has amended its BELVIQ (lorcaserin HCl) marketing and supply agreement with Eisai Co., Ltd. and Eisai Inc. (collectively, “Eisai”). Under the revised agreement, Eisai is acquiring global commercialization rights to BELVIQ, including in the territories retained by Arena under the parties’ prior agreement, with control over global development and commercialization decisions, and is responsible for all lorcaserin development expenses going forward.

The financial terms of the revised agreement are expected to provide Arena with $23 million of cash payments and over $80 million of potential cost relief on current lorcaserin development obligations.

Arena will continue to be eligible to receive royalty payments on net sales of BELVIQ and participate in the upside potential of lorcaserin from additional geographies and clinical trials such as the ongoing cardiovascular outcomes trial, CAMELLIA.

“We would like to thank Eisai for its continued efforts on BELVIQ,” said Amit Munshi, President and Chief Executive Officer of Arena. “This amended agreement allows Arena to focus more of its financial resources on our clinical stage programs, with a goal of developing first- or best-in-class assets with our three proprietary compounds, from which we expect results from multiple Phase 2 clinical trials later this year.”

Under the revised agreement, Arena will:

  • Transfer to Eisai certain intellectual property, assets and records related to lorcaserin
  • Assign its rights under the agreements with Ildong Pharmaceutical Co. LTD., Abic Marketing Limited and CY Biotech Company Limited to Eisai
  • Continue to manufacture lorcaserin at its facility in Switzerland and sell finished product to Eisai for marketing and distribution
  • Provide for technology transfer to Eisai for the option to manufacture lorcaserin

Eisai will be responsible for all further development, sales and marketing, regulatory and patent expenses.

Under the revised agreement,

  • Arena is eligible to receive approximately $23 million over a two-year period for inventory and ongoing support for its manufacturing obligations, plus payments comparable to a contract manufacturer for continuing to supply lorcaserin
  • Arena will no longer incur lorcaserin clinical development expenses, which could have exceeded $80 million over the next several years
  • Arena is eligible to receive royalty payments of 9.5% on annual global net sales of lorcaserin less than or equal to $175 million, 13.5% on annual global net sales greater than $175 million but less than or equal to $500 million and 18.5% on annual global net sales greater than $500 million
  • Arena is eligible to receive $26 million in potential sales and regulatory milestones including $25 million upon global net sales reaching $250 million in any 12 month period and $1 million for approval in Brazil. (Original Source)

Shares of Arena Pharmaceuticals are currently rising 0.67% to $1.51, up $0.01 in after-market trading Wednesday. ARNA has a 1-year high of $2.16 and a 1-year low of $1.30. The stock’s 50-day moving average is $1.48 and its 200-day moving average is $1.62.

On the ratings front, Arena Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on November 8, JMP analyst Jason Butler reiterated a Hold rating on ARNA. Separately, on the same day, Needham’s Alan Carr reiterated a Hold rating on the stock .

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Butler and Alan Carr have a yearly average return of 1.3% and 6.1% respectively. Butler has a success rate of 49% and is ranked #1976 out of 4351 analysts, while Carr has a success rate of 43% and is ranked #545.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers a range of drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.